Abstract As of April 15, 2020, the ongoing coronavirus disease 2019 (COVID-2019)
pandemic has swept through 213 countries and infected more than 1,870,000 individuals …

Fibrosis progression in the lung commonly results in impaired functional gas exchange,
respiratory failure, or even death. In addition to the aberrant activation and differentiation of …

Acute respiratory distress syndrome (ARDS) is a syndrome of acute respiratory failure
caused by noncardiogenic pulmonary edema. Despite five decades of basic and clinical …

Mesenchymal stromal cell‐derived extracellular vesicles (MSC‐EVs) turn out to be a
promising source of cell‐free therapy. Here, we investigated the biodistribution and effect of …

Mesenchymal stromal cells (MSC) have been reported to improve bacterial clearance in
preclinical models of Acute Respiratory Distress Syndrome (ARDS) and sepsis. The …

During acute or chronic lung injury, inappropriate immune response and/or aberrant repair
process causes irreversible damage in lung tissue and most usually results in the …

Chronic lung diseases pose a tremendous global burden. At least one in four people suffer
from severe pulmonary sequelae over the course of a lifetime. Despite substantial …

Mesenchymal stromal cells (MSCs) are currently widely used in cell based therapy
regarding to their remarkable efficacy in controlling the inflammatory status in patients …

On the basis of several preclinical studies, cell-based therapy has emerged as a potential
new therapeutic for acute respiratory distress syndrome (ARDS). Of the various cell-based …

The 2019 novel coronavirus disease (COVID-19), caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has occurred in China and around the world. SARS …